Developing mRNA vaccines to generate broadly neutralizing antibodies for HIV
Combinatorial and computational design of bnAb mRNA vaccines for HIV
['FUNDING_OTHER'] · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · NIH-11124165
This study is testing a new mRNA vaccine that aims to help your immune system create strong defenses against HIV, and it's designed for people living with HIV who want better protection against different strains of the virus.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-11124165 on ClinicalTrials.gov |
What this research studies
This research focuses on creating mRNA vaccines designed to stimulate the immune system to produce broadly neutralizing antibodies (bnAbs) against HIV. By leveraging the unique properties of bnAbs found in individuals with well-controlled HIV, the study aims to develop a vaccine that can effectively target various strains of the virus. The approach involves a sophisticated immunization protocol that mimics natural infection, allowing for a more robust and durable immune response. Patients may benefit from this innovative strategy as it seeks to overcome the challenges faced by previous HIV vaccine candidates.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of HIV infection or those living with HIV who may benefit from enhanced immune responses.
Not a fit: Patients who are not at risk for HIV or those who are already on effective antiretroviral therapy may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to an effective HIV vaccine that provides long-lasting protection against the virus.
How similar studies have performed: While there have been challenges in developing effective HIV vaccines, the concept of using bnAbs has shown promise in other research, indicating potential for success in this novel approach.
Where this research is happening
CAMBRIDGE, UNITED STATES
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ANDERSON, DANIEL G — MASSACHUSETTS INSTITUTE OF TECHNOLOGY
- Study coordinator: ANDERSON, DANIEL G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus